Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond — Credit Rating and Financial Key Figures

Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR number: 30197372) is a company from KØBENHAVN. The company recorded a gross profit of 7463 kDKK in 2025. The operating profit was -888.2 kDKK, while net earnings were -334.2 kDKK. The profitability of the company measured by Return on Assets (ROA) was -1 %, which can be considered poor and Return on Equity (ROE) was -6.6 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 17.5 %, a level that can be considered to be very low. This means the company is highly leveraged, with most assets financed through debt. This high level of financial risk could pose challenges in periods of financial distress or rising interest rates. Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond's liquidity measured by quick ratio was 1.4 which is at a high level. Thus, the company is in a strong financial position, with liquid assets surpassing current liabilities. It is well-prepared to cover short-term financial obligations.